OneMedPlace Interviews Jeffrey Davis, CEO of Access Pharmaceuticals
Last month, OneMedPlace reported on MuGard, a preventive oral mucositis treatment from Dallas-based Access Pharmaceuticals (ACCP). MuGard has performed extremely well in post-approval studies, and is poised to break into a $5 billion worldwide market.
OneMedPlace recently sat down with Jeffrey Davis, CEO of Access Pharmaceuticals, to discuss the clinical success of MuGard and the latest news surrounding the product’s launch.
